Ficus Technology Holdings Limited
細葉榕科技控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 8107)

BUSINESS UPDATE — FRAMEWORK AGREEMENT AND FIRST PURCHASE ORDER FOR MEDICAL DEVICES

This announcement is made by Ficus Technology Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide shareholders and potential investors of the Company with an update on the latest business development of the Group.

The Group is pleased to announce that a subsidiary of the Group has entered into an Annual Procurement Framework Agreement (the "**Agreement**") with Zhejiang Tianliang Biomedical Technology Co., Ltd.* (the "**Buyer**") on 9 July 2026. The Agreement governs the supply of a diversified range of products and related supply chain services by the Group to the Buyer during its term.

The Agreement is valid for two years from 9 July 2026 to 8 July 2028. Under this Agreement, the Buyer may place purchase orders to the Group for products including Class II medical devices, electronic computer servers, and traditional Chinese medicinal agricultural products. The annual consideration is estimated at approximately RMB244 million based on the projected purchase quantities set out in the Agreement. The amount is indicative only and the actual transaction value will depend on the purchase orders actually placed by the Buyer during the term.

On 9 July 2026, the Buyer concurrently placed its first purchase order of Class II medical devices under the Agreement, with an aggregate consideration of RMB4.4 million.

The Group is a professional supply chain service provider with capabilities in product sourcing, quality control and logistics management. The Board believes that entering into the Agreement allows the Group to deploy these core supply chain competencies to serve the Buyer's diversified procurement needs.

This collaboration expands the Group's supply chain service application to cover a wider range of products, demonstrating the scalability and versatility of the Group's supply chain capabilities. The Board considers that the Agreement was entered into on normal commercial terms after arm's length negotiations, is in the ordinary and usual course of business of the Group, and that the terms are fair and reasonable and in the interests of the Company and its shareholders as a whole.

About the Buyer

Zhejiang Tianliang Biomedical Technology Co., Ltd was incorporated on 29 September 2021. Its principal activities include research, development and sales of medical devices spanning Class I, II and III products, as well as pharmaceutical wholesale, retail and import/export of goods.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Mr. Chan Ting
Chairman and Executive Director

Hong Kong, 13 July 2026

As at the date of this announcement, the Board comprises (i) five executive Directors, namely Mr. Chan Ting (Chairman), Ms. Chan Siu Sarah, Ir Prof. Young Andrew Meng Cheung, Mr. Wen Yuan and Mr. Fung King Him Daniel; and (ii) three independent non-executive Directors, namely Dr. Liu Ta-pei, Mr. Choi Man On and Mr. Jan Ting Wai.

This announcement, for which the Directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Group. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this notice is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this notice misleading.

This announcement will remain on the "Latest Listed Company Information" page on the website of the Stock Exchange of Hong Kong Limited at www.hkexnews.hk for a minimum period of seven days from the date of its publication and on the Company's website at www.ficustech.com.

* *English translation denotes for identification purposes only*